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Diabetes and alcohol misuse are two of the major challenges in health systems worldwide. These two diseases finally affect several
organs and systems including the central nervous system. Hippocampus is one of the most relevant structures due to neurogenesis
and memory-related processing among other functions.The present review focuses on the common profile of diabetes and ethanol
exposure in terms of oxidative stress and proinflammatory and prosurvival recruiting transcription factors affecting hippocampal
neurogenesis. Some aspects around antioxidant strategies are also included. As a global conclusion, the present review points out
some common hits on both diseases giving support to the relations between alcohol intake and diabetes.
1. Introduction
In accordance with the International Diabetes Federation,
latest diabetes statistics indicates that 382 million people are
affected by diabetes in 2013. Alcohol use disorder (formerly
called alcohol dependence or alcohol abuse) is the most
abundant mental disorder in America, where approximately
14% of the populationmeets chronic alcoholic criteria during
some period of their lives [1, 2]. It is closely related to
several organic diseases and is involved in almost 50% of
traffic accidents and the majority of homicides, suicides,
and domestic violence cases [3]. Alcoholism and diabetes
can affect several organs and systems. Alcohol exposure and
diabetes can both be associatedwith cognitive impairment. In
fact, diabetes-associated cognitive decline describes a state of
cognitive impairment [4, 5]. Furthermore, diabetes increases
the risk of Alzheimer’s disease, vascular dementia, and any
other type of dementia [6, 7]. Alcoholic dementia and ethanol
related cognitive decline are also described [8–10].
The central nervous system (CNS) is especially vulnerable
to oxidative damage as a result of its high oxygen consump-
tion rate, its abundant lipid content, and relative paucity of
antioxidant enzymes as compared to other tissues. Neural
tissue is particularly sensitive to oxidative insults; in fact
reactive oxygen species (ROS) are involved in many diseases
finally affecting theCNS [11, 12].Under these twopathological
conditions, cellular stress triggers mitochondrial oxidative
damage, which may result in apoptosis and/or necrosis [13–
15].
2. Diabetes and Ethanol Exposure Promote
Oxidative Stress: AGE and Aldehydes
It is well documented that diabetes and alcohol exposure
are accompanied by alterations in the redox status. Hyper-
glycemia and ethanol exposure reduce antioxidant levels and
increase the production of free radicals with subsequent
activation of redox-sensitive genes [15–21].
Glutathione system, including both reduced and oxidized
forms (GSH and GSSG, resp.) and the glutathione peroxidase
enzyme (GPx), is one of the most important cellular antioxi-
dant defense systems due to its capacity of trappingROS.GSH
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is ubiquitously present including the central nervous tissue
[22]. It is well documented that hippocampal GSH/GSSG
ratio and GPx activity are significantly reduced in diabetes
or by ethanol exposure [15, 18–21, 23–26]. Interestingly, this
decrease can be prevented by antioxidant treatment in both
cases [17, 19, 26, 27], indicating that ROS could be at least
partially responsible of the GSH content and GPx activity
decreases.
ROS usually react with lipids, a process known as lipid
peroxidation. Since the CNS is particularly rich in fatty
acids, this peroxidation results in aldehyde production, for
example, malondialdehyde (MDA) and 4-hydroxyalkenals
such as 4-hydroxy-nonenal (4-HNE). These end-products
may create adducts leading to DNA alterations (for a review
see [28]) and protein modifications. These facts can produce
enzymatic activity alterations or lack of DNA sequence-
recognizing, among other side effects. In this way, 4-HNE
inhibits Akt1 by competitive inhibition of ATP at the kinase
domain of ATP binding sites resulting in increasedROS levels
and cell death [29]. ROS production decreased antioxidant
defense and increased lipid peroxidation and membrane
degeneration, leading to cellular damage/death in diabetes or
ethanol exposure [30–32]. In fact, mitochondrial dysfunction
and reduced ATP biosynthesis have been implicated in
diabetes and ethanol exposure [15, 33]. Accumulation of
lipid peroxidation products such as 4-HNE and MDA in
mitochondria has also been reported in diabetic patients,
possibly causing further damage to mitochondrial genetic
and metabolic systems [34, 35]. In this sense, recent data
from our laboratory indicate a marked increase in 4-HNE
aggregates after ethanol exposure in a human retinal pigment
epithelial cell line (ARPE-19) accompanied by mitochondrial
degeneration and mitophagy [36].
One of the main questions concerning ethanol and
diabetes is the one related to how hyperglycemia and ethanol
exposure exert primarily their negative effects. Evidences are
accumulating pointing to the role of oxidative stress and
proinflammatory mechanisms on both pathological condi-
tions, but little is known about the molecular mechanisms.
Circulating proteins or lipids can be modified by circu-
lating sugars and even aldehydes such as acetaldehyde [37,
38]. These products are known as advanced glycation end
products (AGEs) [39, 40]. AGEs can produce ROS and AGEs
can bind to specific cell surface receptors (RAGE) [40, 41].
AGEs produce ROS via NAD(P)H oxidase and also activate
nuclear factor kappa B (NF-𝜅B) [20, 42]. Further support for
this idea is the finding of increased expression of serumAGEs
in alcoholic patients and RAGE in the prefrontal cortex of
human alcoholic patients [43, 44]. In fact, some toxic effects
promoted by experimental diabetes are increased by ethanol
administration [45].
3. Cytochrome p450 2E1 (CYP2E1) Is
Commonly Implicated
Another relevant enzyme related to diabetes and ethanol
exposure is cytochrome P450. This is a family of enzymes
involved in the oxidativemetabolismof both endogenous and
xenobiotic products [46–48]. Particularly involved in EtOH
oxidation, CYP2E1 isoform assumes an important role in
metabolizing ethanol being considered as amajor component
of the microsomal ethanol-oxidizing system (MEOS) [49,
50].
Increased expression of hepatic CYP2E1 in human or
experimental diabetes and alcohol abusers has been reported
[51–54]. Ethanol-induced CYP2E1 gene transcription is ROS-
mediated and therefore CYP2E1 induction is accompanied
by more ROS production and vice versa [55]. In fact, diallyl
sulphide (DAS), a competitive inhibitor of CYP2E1, can
directly block ROS production and also inhibit CYP2E1
induction [55]. A parallel increase of CYP2E1 expression and
ROS production in brain, kidney, and liver of streptozotocin-
induced diabetic rats has been also reported and these
increases can be blocked by ascorbic acid [56, 57]. So
CYP2E1 and ROS are reciprocally modulated in diabetes
and ethanol exposure. Interestingly, NF-𝜅B regulates CYP2E1
expression by different ways, being implicated in several
diseases including diabetes [58]. Considering that CYP2E1
is not only found in liver, but can be also considered
almost ubiquitously present, the possibility that an ethanol
extrahepatic detoxifying activity could be present in other
tissues, including the brain, must be taken into account.
4. Hippocampal Neurogenesis Is Affected in
Diabetes and Ethanol Exposure
Hippocampus is part of the temporal lobe being considered
crucial for several cognitive processes as well as for spa-
tial navigation and memory processing [59]. Hippocampus
is particularly affected in several diseases, for example,
Alzheimer’s disease and diabetes, or in alcohol use disorder
[60, 61]. One of the particularities of this neural structure
is that referred to neurogenesis. Hippocampus shares this
privilege with the subventricular zone (SVZ). Concretely,
the subgranular zone (SGZ) of the dentate gyrus presents
a discrete stem cell population [62]. Newborn subgranular
cells differentiate to neurons being finally integrated into
the granular cell layer (GCL) thickness [63]. Although the
concrete function or meaning of this neuronal incorpora-
tion still remains unclear [64], the inhibition of stem cell
proliferation or the death of newborn cells is accompanied
by an impairment of hippocampal-dependent functions.
Focusing on diabetes and alcohol consumption, it is well
established that both conditions can affect cognitive processes
and neurogenesis.
A classical experimental task evaluating hippocampal-
dependent functions is the popular Morris water maze test,
based on the location of an underwater hidden platform.
Independently of the swimming speed, animals treated with
ethanol exhibit more latency time to find the platform.
In other words they need more time to learn. This task
is considered a good tool assessing hippocampal function.
Giving support to this phenomenon is the finding that
hippocampal long term potentiation (LTP) is also disrupted.
Experimental LTP is considered as a good tool to approach
synaptic plasticity and therefore learning processes [65].
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Interestingly the simultaneous triad consisting of neuro-
genesis reduction, spatial navigation impairment, and hip-
pocampal LTP disruption is usually present in diabetes and
ethanol exposure [17, 19, 66–68], suggesting close relation-
ship among them. Furthermore, all these alterations can be
prevented by antioxidant treatment adding more evidence
to this relationship [19, 68]. Although it seems clear that
ROS are relevant in these processes, evidences are also
accumulating pointing to the glucocorticoid pathway, since
it has been demonstrated how those hippocampal alterations
(including neurogenesis, LTP, and water maze test) in type
I and II diabetes are normalized when glucocorticoid levels
are in a physiological range [69]. The negative effects of
high glucocorticoid levels on hippocampal neurogenesis and
synaptic plasticity are well documented [69–72]. Ethanol
exposure also alters the hypothalamic pituitary axis (HPA): in
a rat model of binge drinking, increased corticosterone levels
led to dentate gyrus degeneration and this phenomenon
seemed to be mediated by type II glucocorticoid receptor
[73], in agreement with that occurring in diabetes.
5. CREB, NF-𝜅B, and Nrf2 Are Altered in
Diabetes and Alcohol Exposure
NF-𝜅B and cAMP responsive element-binding protein
(CREB) are both transcription factors, respectively, related
with proinflammatory and prosurvival genes.
CREB-related genes are transcribed by the phosphoryla-
tion of CREB (p-CREB).ThoseCREB-related genes encoding
neurotrophins are generally related to neuronal survival,
cell death protection, and neural plasticity, as are the brain
derived neurotrophic factor (BDNF), B-cell lymphoma 2
(Bcl-2) protein, nerve growth factor (NGF), and vascular
endothelial growth factor (VEGF) genes [74, 75].
CREB/p-CREB signaling has been related to neurite out-
growth, learning-memory and LTP [76–78].
Although NF-𝜅B is a transcriptional factor typically
implicated in inflammatory and immune responses [79], NF-
𝜅B is also involved in neuroprotection, being implicated in
cell division, synaptic plasticity, neurite growth, and forma-
tion of functional dendritic spines [79–83].
NF-𝜅B can be activated by oxidative stress or other signals
such as cytokines or glutamate [79, 82, 84]. In fact, NF-𝜅B
is induced in several conditions such as neurodegenerative
diseases and brain injury [81, 85, 86].
As indicated above, ethanol exposure and diabetes pro-
mote oxidative stress in the CNS and particularly in the
hippocampus. At the same time both, ethanol exposure and
diabetes, decrease hippocampal CREB phosphorylation [18,
87, 88] while they increase NF-𝜅B activity [17, 18, 88]. Addi-
tionally, deregulation of inflammatory genes has been found
in hippocampi of alcoholic patients [89] and furthermore
prefrontal cortices from alcoholic patients also show NF-
𝜅B/p50 downregulation [90].
Ethanol-induced p-CREB decrease is accompanied by
reductions in BDNF gene expression contributing to hip-
pocampal neurotoxicity [91]. In fact, hippocampal BDNF
is also decreased in a type 2 diabetes animal model and it
is associated with hippocampal dependent memory impair-
ment [92, 93]. Furthermore, caffeine and huperzine restore
hippocampal-dependentmemory impairment via BDNF [94,
95].
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) binds
to the antioxidant response element (ARE) sequence pro-
moting the transcription of antioxidant-related proteins
as NAD(P)H quinone oxidoreductase 1, gluthatione S-
transferase, or GPx among others [96]. According to Ceder-
baum [97] Nrf2 plays a key role in the adaptive response
against increased oxidative stress caused by CYP2E1 in
HepG2 cells. Nrf2 activation inhibits NF-𝜅B activation by
reducing ROS and by inhibiting I𝜅B degradation [97, 98].
NF-𝜅B also binds to ARE sequence competing with Nrf2
[99] and therefore the result of this balance may lead to
proinflammation or antioxidant defense responses.
Focusing on hippocampal neurogenesis, a positive reg-
ulation of cell proliferation has been demonstrated by p-
CREB in the SGZ [100]. Stressing the role of CREB in
this process, hippocampal neurogenesis is also a GABA-
CREB dependent process regulating maturation and survival
of newly generated subgranular neurons [101]. All these
evidences give support to the possibility that ethanol and
diabetes may reduce hippocampal neurogenesis in the same
way.
According to previous reports [80–82], NF-𝜅B may play
different roles in hippocampal neurogenesis depending on
the cell stage. In neuronal progenitor cells (NPC) it regulates
axogenesis and maturation, whereas in mature granule cells
(MGC) it regulates neuroprotection and synaptic trans-
mission. In fact NF-𝜅B inhibition promotes dentate gyrus
atrophy [80].
How some genes related to neurogenesis and synaptic
plasticity are altered by diabetes as well as how dietary
supplementation with resveratrol normalized them has been
described. Furthermore, proinflammatory genes from the
Jak-Stat pathway are also repressed after resveratrol admin-
istration [102]. In this sense, it is interesting to note that
resveratrol acts as a mixed agonist/antagonist for estrogen
receptors [103] that induces Bcl-2 expression via CREB and
Akt phosphorylation [104], so its action is not solely by direct
ROS trapping [105].
Regarding the CREB-related pathway, it has been shown
that Nrf2 and NF-𝜅B compete for the transcriptional coac-
tivator CREB-binding protein (CBP) [106]. Additionally,
CBP/p300 complex is a histone acetyltransferase (HAT) asso-
ciated with CREB, Nrf2, NF-𝜅B, and AP-1 gene transcription
[107]. However, CBP is also associated with glucocorticoid
receptors [108], resulting in HAT activity inhibition with
subsequent transcriptional blockade of the genes above;
interestingly, curcumin has been described as an inhibitor of
CBP/p300 [109]. Several data are focusing on the neuropro-
tective role of curcumin improving hippocampal neurogene-
sis in some animal models such as ischemic brain injury [110]
and chronic stress [111]. Curcumin alleviates neuropathic
pain by reducing spinal BDNF and cox-2 gene expression
in a rat model of neuropathic pain [112], and interestingly
the Akt/Nrf2 pathway is involved in neuroprotection after
brain ischemia [113]. However and surprisingly, hippocampal
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Figure 1: Scheme summarizing common pathways implicated in oxidative stress, inflammation, and antioxidant responses. 1. Circulating ethanol
and high glucose levels lead to ROS production, antioxidant defense decay, AGE, and aldehyde production (4-HNE, MDA). Alterations
on the hypothalamic pituitary axis (HPA) produce glucocorticoid release. 2. RAGE activation and ROS activate Akt but increased levels
of 4-HNE; MDA can block Akt phosphorylation. 3. CBP is an acetyl transferase (HAT) that depends on p-Akt. CBP is necessary for
p-CREB, Nf-𝜅B, and Nrf2 allowing transcription of proinflammatory or anti-inflammatory genes. Glucocorticoid receptors inhibit CBP
activity blocking transcription. Since Nf-𝜅B, p-CREB, and Nrf2 compete for CBP the balance on proinflammation versus anti-inflammation
transcription is compromised. GSH: reduced glutathione; NF-𝜅B: nuclear factor kappa B; MDA: malondialdehyde; ROS: reactive oxygen
species; MnSOD: manganese superoxide dismutase; TNF𝛼: tumor necrosis factor alpha; COX: cyclooxygenase; iNOS: inducible nitric oxide
synthase; GPx: glutathione peroxidase; BDNF: brain-derived neurotrophic factor; NGF: nerve growth factor; Bcl-2: B-cell lymphoma 2;
CORT: corticosteroid; CORT-R: corticosteroid receptor; P-CREB: phospho-cAMP response element-binding; CBP: CREB-binding protein;
Nrf2: nuclear factor erythroid-derived 2; 4-HNE: 4-hydroxynonenal; Akt: protein kinase B; CYP2E1: cytochrome P450 2E1; RAGE: receptor
for advanced glycation end products.
neurogenesis inhibition, under chronic stress conditions, can
be reversed by curcumin via increasing BDNF [110].
High glucose and ethanol exposure promote glucose
misbalance, HPA deregulation with metabolic andmolecular
changes affecting different systems but particularly CNS.
ROS and oxidative stress misbalance are present as common
background feature and may be the reason of the similarities
observed between high glucose and ethanol exposure such as
the presence of AGE, good outcome to antioxidant strategies,
and hippocampal neurogenesis inhibition. Since alcoholism
and diabetes in humans are long lasting diseases with a
“waveform-like” behavior in terms of intermittent relapse-
abstinence, binge or chronic drinking, randomly insulin
control, or uncontrolled glycemia, it seems plausible that
alcoholism and diabetes may lead to neuroadaptive changes.
Transcription signaling for CREB, Nrf2, and NF-𝜅B
dependent genes is commonly regulated by CBP activity
and furthermore the competition for DNA sequences might
explain the outcome of these diseases. Exposure to high
glucose levels or ethanol seems to act on a similar way
activating similar genes and some antioxidants as curcumin
or resveratrol are effective by activating up-streammolecules
modulating those aforementioned genes. ROS inhibition sig-
nificantly alleviates many of the deleterious effects promoted
by hyperglycemia or ethanol exposure. So the combination
of direct ROS scavengers and antioxidants as curcumin or
resveratrol can not only block cellular damage but also
modulate gene transcription activity (see Figure 1).
6. Final Summary
Several cellular and molecular alterations are shared during
ethanol exposure or under diabetic conditions. Hippocampal
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neurogenesis is negatively affected and CREB/p-CREB, NF-
𝜅B, Nrf2, and CYP 2E1 are involved and modified in both
situations. Oxidative stress is a key factor of these situa-
tions, since the addition of antioxidants (trapping ROS) can
reverse or normalize all these aforementioned alterations.
Furthermore, evidences are also focusing on downstream
effects of antioxidants in terms of activation-repression of
transcription factors such as CREB or Nrf2, making of
antioxidant therapies a good tool against neural and func-
tional alterations in diabetes and alcohol-related memory
or cognitive impairments. Diabetes and chronic ethanol
exposure affect different organs and systems and some of
their negative effects can be improved or prevented by
antioxidant therapies. Knowing how antioxidants can prevent
those negative effects or elicit cellular protective responses
may be helpful for future development of new therapeutic
tools against these two diseases affecting millions of people
worldwide.
Additionally, experimental and clinical studies strongly
indicate a close relationship between alcohol intake and risk
of diabetes development [114–117]. Considering all data avail-
able, and reviewed herein (molecular signaling, genes, and
transcription factors), it seems plausible that all overlapping
mechanisms of alcohol intake and diabetes could explain this
relationship.
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